Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C virus (HCV) is chiefly transmitted by blood-to-blood contact. When the blood of a person with hepatitis C enters the bloodstream of another person,...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • Hepatitis C virus treatment

    The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally). Interferons are human proteins that...

    From: HIV treatments directory

    Information level Level 4

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Next-generation HCV treatments should benefit challenging patient groups

    Despite treatment success rates of 95 percent and better, hepatitis C (HCV) therapy can still improve. Finding a universal cure is the goal, according to Michael Fried, MD, professor of medicine and director of the UNC Liver Center at the University of North Carolina, Chapel Hill.

    23 May 2016 | Digestive Disease Week blog
  • The Hepatitis C Trust is considering seeking a judicial review of NHS England’s decision to ration access to hepatitis C treatment

    The Hepatitis C Trust wrote to NHS England to ask it to reconsider its decision to limit the number of people with hepatitis C who are allowed access to new NICE approved drugs that cure the disease. On Monday 16th May, 2016 NHS England replied with a response that The Hepatitis C Trust did not find satisfactory. With great regret it now has to consider seeking a judicial review of the decision.

    18 May 2016 | Hepatitis C Trust
  • Philip Christopher Baldwin: “We need better access to treatment for gay men living with HIV and Hep C”

    I am saddened by the delay in the provision of Hep C treatment in the UK. Of the 103,700 people living with HIV in the UK, nine per cent are co-infected with Hep C, many of them gay men. It is unfair that we have to cope with Hep C without help. We have a treatment which can cure Hep C, but the treatment is being withheld by the NHS for funding reasons.

    11 May 2016 | Gay Times
  • Covering Costly HCV Tx: Who Makes that Call?

    Forcing U.S. states to cover pricey treatments for people with the hepatitis C virus (HCV) would cause the Medicaid budget to "explode," according to a Medicaid representative.

    11 May 2016 | MedPage Today HIV/AIDS
  • It’s Time to End Insurance Restrictions on Life-Saving Hepatitis C Treatments

    As consensus on the shortsightedness of insurance restrictions on life-saving hepatitis C treatments continues to build, it’s time for private insurers and Medicaid programs to give all Americans suffering from this devastating disease a chance at a cure.

    10 May 2016 | American Journal of Managed Care
  • Study: Cheaper to cure hepatitis C sooner than later

    Although it would take a huge investment at the outset, treating hepatitis C patients could save $800 billion in the next 20 years and free up treatment for thousands of people with other liver disease.

    10 May 2016 | UPI.com
  • A Way Out of the Dismal Arithmetic of Hepatitis C Treatment

    This special issue of The American Journal of Managed Care presents important new peer-reviewed research about the consequences of this dismal arithmetic of HCV treatment. The papers cover ground ranging from the out-of-pocket costs of a DAA treatment course to the real-world consequences—both economic and clinical—of failing to treat.

    10 May 2016 | American Journal of Managed Care
  • Gilead's $1000 hepatitis C pill gets patent in India

    In what could be a major setback to access to treatment in high-burden countries, the Indian Patent Office on Monday granted a patent to Gilead Pharmasset on Sovaldi (sofosbuvir), its blockbuster drug for hepatitis C, for which the company charges $1,000 per pill in the US.

    10 May 2016 | Times of India
  • Sky-high price of hepatitis C drug produces profits for lawmakers

    While patients in Massachusetts await affordable doses of the blockbuster hepatitis C drug Sovaldi, Rep. Joseph Kennedy III has financially benefited from the success of the drug’s manufacturer, Gilead Sciences, according to public financial disclosures and campaign finance records.

    05 May 2016 | Center for Responsive Politics
  • Antiviral therapies give Hepatitis C cirrhosis patients similar life expectancy as general population

    The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology.

    05 May 2016 | Eurekalert Medicine & Health
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.